Literature DB >> 4346614

Treatment of metastatic trophoblastic disease: good and poor prognosis.

C B Hammond, L G Borchert, L Tyrey, W T Creasman, R T Parker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4346614     DOI： 10.1016/0002-9378(73)90389-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


× No keyword cloud information.
  12 in total

1.  High-risk molar disease.

Authors:  G W Chapman; J B Mailhes
Journal:  J Natl Med Assoc       Date:  1991-11       Impact factor: 1.798

2.  Follow-up of molar pregnancy.

Authors:  W E Lucas
Journal:  West J Med       Date:  1975-01

3.  Update in cancer chemotherapy: genitourinary tract cancer, Part 7: Gestational trophoblastic neoplasms.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-07       Impact factor: 1.798

4.  Hepatic scintigraphic changes associated with gestational trophoblastic disease.

Authors:  E H Sumers; R S Berkowitz; A M Wang; D E Drum; D P Goldstein
Journal:  Eur J Nucl Med       Date:  1990

5.  The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma.

Authors:  E S Newlands; K D Bagshawe
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  Treatment of gestational trophoblastic tumors.

Authors:  John R Lurain
Journal:  Curr Treat Options Oncol       Date:  2002-04

Review 7.  Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.

Authors:  Mo'iad Alazzam; John Tidy; Raymond Osborne; Robert Coleman; Barry W Hancock; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2016-01-13

Review 8.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia.

Authors:  Mo'iad Alazzam; John Tidy; Barry W Hancock; Raymond Osborne; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

9.  Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.

Authors:  L S Dobson; P C Lorigan; R E Coleman; B W Hancock
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

Review 10.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia.

Authors:  Theresa A Lawrie; Mo'iad Alazzam; John Tidy; Barry W Hancock; Raymond Osborne
Journal:  Cochrane Database Syst Rev       Date:  2016-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.